|Primary analysis complete
|Study Start Date:
|Study Made Public:
A Phase 1b clinical trial to evaluate the safety and immunogenicity of a recombinant adenoviral serotype 35 (rAd35) and serotype 5 (rAd5) HIV-1 vaccines when given in heterologous prime-boost regimens or as a boost to a recombinant DNA vaccine in healthy, HIV-1 uninfected adult participants with pre-existing immunity to adenovirus serotype 5 infection
HVTN 072 is a Phase Ib clinical trial to evaluate the safety and immunogenicity of prime/boost regimens using combinations of VRCHIVADV027-00-VP (rAd35), VRCHIVADV038-00-VP (rAd5), and VRC-HIVDNA044-00-VP (DNA).
Sign in to see full information about this study and to download study data.
ProductsProduct info coming soon!
No integrated data is available for this study.
No non-integrated data is available for this study.